Patient Priorities Concerning Treatment Decisions for Advanced Neuroendocrine Tumors Identified by Discrete Choice...

Area of Science:

• Oncology
• Medical Economics
• Patient-Reported Outcomes

Background:

• Advanced neuroendocrine tumors (NETs) present diverse treatment choices.
• Discrepancies exist between physician and patient priorities regarding treatment attributes like adverse event (AE) rates.
• Understanding patient preferences is crucial for patient-centered decision-making in NET management.

Purpose of the Study:

• To elicit treatment preferences of patients with advanced midgut and pancreatic NET (pNET).
• To determine relative utility rankings for treatment attributes including progression-free survival (PFS), treatment modality, and AE rates.
• To identify patient priorities for specific NET treatment profiles.

Main Methods:

• Utilized two discrete choice experiments (DCEs) employing the potentially all pairwise rankings of all possible alternatives (PAPRIKA) method.
• Elicited preferences from 110 midgut NET and 132 pNET patients.
• Attribute levels were derived from randomized clinical trial data for NET treatments.

Main Results:

• Longer PFS was the primary preference for the majority of participants (64.5% midgut, 59% pNET).
• Approximately 40% of participants prioritized lower AE rates or less invasive modalities over PFS.
• In midgut NETs, 60.9% favored peptide receptor radionuclide therapy (PRRT) and 30.0% favored somatostatin analogue dose escalation.

Conclusions:

• Neuroendocrine tumor patients exhibit heterogeneous treatment priorities.
• Patient preferences vary regarding progression-free survival, adverse events, and treatment invasiveness.
• Shared decision-making is essential for optimizing treatment choices in NET patients.